| [1] |
Liu H, Zeng Z, Zhang H, et al. Morbidity, Mortality, and Pathologic Outcomes of Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer Short-term Outcomes From a Multicenter Randomized Controlled Trial [J]. Ann Surg, 2023, 277(1): 1-6.
|
| [2] |
Kang L, Zeng Z, Liu H. Three-year disease-free survival after transanal vs. laparoscopic total mesorectal excision for rectal cancer (TaLaR): A randomized clinical trial [J]. J Clinic Oncol, 2024, 42(16_suppl): 3516-3518.
|
| [3] |
Serra-Aracil X, Zarate A, Bargalló J, et al. Transanal versus laparoscopic total mesorectal excision for mid and low rectal cancer (Ta-LaTME study): multicentre, randomized, open-label trial [J]. Br J Surg, 2023, 110(2): 150-158.
|
| [4] |
姚宏伟, 张忠涛, 郑民华. 直肠癌经肛全直肠系膜切除中国专家共识及临床实践指南（2019版）[J]. 中国实用外科杂志, 2019, 39(11): 6-13.
|
| [5] |
Gardner IH, Kelley KA, Abdelmoaty WF, et al. Transanal total mesorectal excision outcomes for advanced rectal cancer in a complex surgical population [J]. Surg Endosc, 2022, 36(1): 167-175.
|
| [6] |
Uematsu D, Akiyama G, Sugihara T, et al. Transanal Total Pelvic Exenteration With Sphincter-Preserving Surgery[J]. Dis Colon Rectum, 2018, 61(5): 641.
|
| [7] |
Uematsu D, Akiyama G, Sugihara T, et al. Transanal Total Pelvic Exenteration: Pushing the Limits of Transanal Total Mesorectal Excision With Transanal Pelvic Exenteration[J]. Dis Colon Rectum, 2017, 60(6): 647-648.
|
| [8] |
Xu J, Tang B, Li T, et al. Robotic colorectal cancer surgery in China: a nationwide retrospective observational study[J]. Surg Endosc, 2021, 35(12): 6591-6603.
|
| [9] |
Jayne D, Pigazzi A, Marshall H, et al. Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal Cancer: The ROLARR Randomized Clinical Trial[J]. Jama, 2017, 318(16): 1569-1580.
|
| [10] |
Feng Q, Yuan W, Li T, et al. Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial [J]. Lancet Gastroenterol Hepatol, 2022, 7(11): 991-1004.
|
| [11] |
Liu Y, Wang Y, Wang C, et al. Comparison of short-term outcomes of robotic-assisted radical colon cancer surgery using the Kangduo Surgical Robotic System and the Da Vinci Si Robotic System: a prospective cohort study [J]. Int J Surg, 2024, 110(3): 1511-1518.
|
| [12] |
中国医师协会结直肠肿瘤专业委员会机器人手术专业委员会, 中国研究型医院学会机器人与腹腔镜外科专业委员会, 许剑民, 等. 机器人结直肠癌手术中国专家共识（2020版）[J]. 中国实用外科杂志, 2021, 41(01): 12-19.
|
| [13] |
国家卫生健康委员会医政司, 中华医学会肿瘤学分会, 顾晋, 等. 国家卫健委中国结直肠癌诊疗规范（2023版）[J]. 中国实用外科杂志, 2023, 43(06): 602-630.
|
| [14] |
Scott AJ, Kennedy EB, Berlin J, et al. Management of Locally Advanced Rectal Cancer: ASCO Guideline[J]. J Clin Oncol, 2024, 42(28): 3355-3375.
|
| [15] |
Turri G, Ostuzzi G, Vita G, et al. Treatment of Locally Advanced Rectal Cancer in the Era of Total Neoadjuvant Therapy: A Systematic Review and Network Meta-Analysis[J]. JAMA Netw Open, 2024, 7(6): e2414702.
|
| [16] |
Dijkstra EA, Nilsson PJ, Hospers GAP, et al. Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial [J]. Ann Surg, 2023, 278(4): e766-e772.
|
| [17] |
Bahadoer RR, Dijkstra EA, Van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(1): 29-42.
|
| [18] |
Verheij FS, Omer DM, Williams H, et al. Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase Ⅱ OPRA Trial [J]. J Clin Oncol, 2024, 42(5): 500-506.
|
| [19] |
Fokas E, Schlenska-Lange A, Polat B, et al. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial [J]. JAMA Oncol, 2022, 8(1): e215445.
|
| [20] |
Schrag D, Shi Q, Weiser MR, et al. Preoperative Treatment of Locally Advanced Rectal Cancer [J]. N Engl J Med, 2023, 389(4): 322-334.
|
| [21] |
Mei WJ, Wang XZ, Li YF, et al. Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase Ⅲ Trial [J]. Ann Surg, 2023, 277(4): 557-564.
|
| [22] |
Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers [J]. Nat Med, 2020, 26(4): 566-576.
|
| [23] |
Cercek A, Lumish M, Sinopoli J, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer[J]. N Engl J Med, 2022, 386(25): 2363-2376.
|
| [24] |
Hu H, Kang L, Zhang J, et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial [J]. Lancet Gastroenterol Hepatol, 2022, 7(1): 38-48.
|
| [25] |
Yang Z, Gao J, Zheng J, et al. Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study[J]. Signal Transduct Target Ther, 2024, 9(1): 56.
|
| [26] |
Lin ZY, Zhang P, Chi P, et al. Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phaseⅢtrial [J]. Ann Oncol, 2024, 35(10): 882-891.
|
| [27] |
Xia F, Wang Y, Wang H, et al. Randomized Phase Ⅱ Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH) [J]. J Clin Oncol, 2024, 42(28): 3308-3318.
|
| [28] |
George TJ, Yothers G, Rahma OE, et al. Long-term results from NRG-GI002: A phase Ⅱ clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC) [J]. J Clinic Oncol, 2023, 41(4_suppl): 7-10.
|
| [29] |
Tsukada Y, Bando H, Inamori K, et al. Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer [J]. Br J Cancer, 2024, 131(2): 283-289.
|
| [30] |
Custers PA, Beets GL, Bach SP, et al. An International Expert-Based Consensus on the Definition of a Clinical Near-Complete Response After Neoadjuvant (Chemo) radiotherapy for Rectal Cancer [J]. Dis Colon Rectum, 2024, 67(6): 782-795.
|
| [31] |
Wang L, Zhang XY, Zhao YM, et al. Intentional Watch and Wait or Organ Preservation Surgery Following Neoadjuvant Chemoradiotherapy Plus Consolidation CAPEOX for MRI-defined Low-risk Rectal Cancer: Findings From a Prospective Phase 2 Trial (PKUCH-R01 Trial, NCT02860234) [J]. Ann Surg, 2023, 277(4): 647-654.
|
| [32] |
中国直肠癌新辅助治疗后等待观察数据库研究协作组, 中华医学会外科学分会结直肠外科学组, 中国医师协会结直肠肿瘤医师专业委员会, 等. 直肠癌新辅助治疗后等待观察策略中国专家共识（2024版）[J]. 中华胃肠外科杂志, 2024, 27(04): 301-315.
|
| [33] |
Rullier E, Vendrely V, Asselineau J, et al. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial[J]. Lancet Gastroenterol Hepatol, 2020, 5(5): 465-474.
|
| [34] |
Serra-Aracil X, Pericay C, Badia-Closa J, et al. Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab, N0, M0 rectal cancer: a multicentre randomised, controlled, phase Ⅲ trial (the TAU-TEM study) [J]. Ann Oncol, 2023, 34(1): 78-90.
|
| [35] |
郑民华, 将天宇, 赵轩等. 中国腹腔镜直肠癌根治术30年发展历程与未来[J/CD]. 中华普外科手术学杂志（电子版）, 2024, 18(06): 591-596.
|
| [36] |
池畔, 黄胜辉. 中国腹腔镜直肠癌根治术30年的巨大进步[J/CD]. 中华普外科手术学杂志（电子版）, 2024, 18(06): 596-601.
|